ProQR Therapeutics N.V.
PRQRNASDAQHealthcareBiotechnology
As of Oct 22, 2026 close
- Market cap
- $146.24M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $1.30$3.10
- Volume (live)
- -
- Avg. volume (3M)
- 769.00K
ProQR Therapeutics (PRQR) Stock Price & Financial Analysis
ProQR Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $1.32 - $1.39 |
|---|---|
| 52-Week High | $3.10 |
| 52-Week Low | $1.30 |
| Open | $1.36 |
| Volume (last close) | 566.81K |
| Average Volume (3M) | 769.00K |
| Revenue (TTM) | 20.79M |
|---|---|
| Net Income (TTM) | -47.54M |
| Free Cash Flow (TTM) | -56.39M |
| EPS (TTM) | −$0.45 |
| Profit Margin | -228.70% |
| Operating Margin | -232.34% |
| Return on Equity (ROE) | -53.37% |
| Debt to Equity | 0.17 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Market Cap | 146.24M |
|---|---|
| Shares Outstanding | 109.96M |
| Price to Sales (P/S) | 7.04 |
| Price to Book (P/B) | 1.64 |
| EV/EBITDA | -0.70 |
| 50-Day MA | $1.86 |
|---|---|
| 200-Day MA | $1.71 |
| 1-Year Change | −52.84% |
Source: Market prices and company fundamentals. Data as of Oct 22, 2026. Data sources and methodology
ProQR Therapeutics at a Glance
As of the Oct 22, 2026 close, ProQR Therapeutics (PRQR) has a market capitalization of $146.24M. The stock trades at 7.0× sales. Over the trailing twelve months it lost $47.54M on revenue of $20.79M and burned $56.39M of free cash flow. Revenue grew 10.6% year over year.
As of its latest reported balance sheet, it holds $131.26M in cash and securities against $14.79M of debt, a net cash position of $116.47M.
ProQR Therapeutics does not currently pay a dividend.
The share price is down 52.8% over the past year. At $1.33 (the Oct 22, 2026 close) it sits near the bottom of its 52-week range of $1.30 to $3.10, below its 200-day moving average of $1.71.
Based on 4 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $8.25, 520.3% above the Oct 22, 2026 close.
Frequently Asked Questions About ProQR Therapeutics
What is the current stock price for PRQR?
As of the Oct 22, 2026 close, PRQR stock trades at $1.33. The 52-week range is $1.30–$3.10, with a day range of $1.32–$1.39.
What is the P/E ratio for PRQR?
The P/E ratio (Price-to-Earnings) for PRQR is shown in the Key Statistics section. This valuation metric helps compare ProQR Therapeutics N.V. to industry peers.
Does PRQR pay dividends?
ProQR Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for PRQR?
Based on ratings from 4 professional analysts over the last 90 days, the consensus for PRQR is Buy. The average 12-month price target is $8.25, a 520.3% upside from the Oct 22, 2026 close of $1.33.
What is the market cap of PRQR?
As of the Oct 22, 2026 close, ProQR Therapeutics's market capitalization is $146.2M, classifying it as a micro-cap company. ProQR Therapeutics operates in the Healthcare sector within the Biotechnology industry.